Antioxidants in the canine model of human aging

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 5, 2012, Pages 685-689

  Dowling, Amy L S ^a   Head, Elizabeth ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's disease; Beta amyloid; Cognition; Dog; Lipoic acid; Vitamins

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CARNITINE; THIOCTIC ACID;

AGING; ALZHEIMER DISEASE; COGNITIVE DEFECT; DOG; LONGITUDINAL STUDY; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

AGING; ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; DOGS; HUMANS; MODELS, ANIMAL; OXIDATIVE STRESS;

ANIMALIA; CANIS FAMILIARIS;

EID: 84858156551     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.09.020     Document Type: Review

References (120)

1. Poon H.F., Calabrese V., Scapagnini G., Butterfield D.A. Free radicals and brain aging. Clin. Geriatr. Med. 2004, 20:329-359.
2. Liu J., Mori A. Stress, aging, and brain oxidative damage. Neurochem. Res. 1999, 24:1479-1497.
3. Ames B.N., Shigenaga M.K. Oxidants are a major contributor to aging. Ann. N. Y. Acad. Sci. 1992, 663:85-96.
4. Ames B.N., Shigenaga M.K., Hagen T.M. Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:7915-7922.
5. Shulman R.G., Rothman D.L., Behar K.L., Hyder F. Energetic basis of brain activity: implications for neuroimaging. Trends Neurosci. 2004, 27:489-495.
6. Halliwell B., Gutteridge J.M.C. Oxygen radicals in the nervous system. Trends Neurosci. 1985, 8:22-26.
7. Floyd R.A., Hensley K. Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol. Aging 2002, 23:795-807.
8. Perez-Campo R., Lopez-Torres M., Cadenas S., Rojas C., Barja G. The rate of free radical production as a determinant of the rate of aging: evidence from the comparative approach. J. Comp. Physiol. B 1998, 168:149-158.
9. Liu J., Atamna H., Kuratsune H., Ames B.N. Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites. Ann. N. Y. Acad. Sci. 2002, 959:133-166.
10. Mori A., Utsumi K., Liu J., Hosokawa M. Oxidative damage in the senescence-accelerated mouse. Ann. N. Y. Acad. Sci. 1998, 854:239-250.
11. Nakahara H., Kanno T., Inai Y., Utsumi K., Hiramatsu M., Mori A., Packer L. Mitochondrial dysfunction in the senescence accelerated mouse (SAM). Free Radic. Biol. Med. 1998, 24:85-92.
12. Mecocci P., MacGarvey U., Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 1994, 36:747-751.
13. Wei Y.H. Oxidative stress and mitochondrial DNA mutations in human aging. Proc. Soc. Exp. Biol. Med. 1998, 217:53-63.
14. Shigenaga M.K., Hagen T.M., Ames B.N. Oxidative damage and mitochondrial decay in aging. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:10771-10778.
15. Hirai K., Aliev G., Nunomura A., Fujioka H., Russell R.L., Atwood C.S., Johnson A.B., Kress Y., Vinters H.V., Tabaton M., Shimohama S., Cash A.D., Siedlak S.L., Harris P.L., Jones P.K., Petersen R.B., Perry G., Smith M.A. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 2001, 21:3017-3023.
16. Miquel J., Economos A.C., Fleming J., Johnson J.E. Mitochondrial role in cell aging. Exp. Gerontol. 1980, 15:575-591.
17. Wallace D.C. Mitochondrial genetics: a paradigm for aging and degenerative diseases?. Science 1992, 256:628-632.
18. Haripriya D., Devi M.A., Kokilavani V., Sangeetha P., Panneerselvam C. Age-dependent alterations in mitochondrial enzymes in cortex, striatum and hippocampus of rat brain - potential role of L-Carnitine. Biogerontology 2004, 5:355-364.
19. Mecocci P., MacGarvey U., Kaufman A.E., Koontz D., Shoffner J.M., Wallace D.C., Beal M.F. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann. Neurol. 1993, 34:609-616.
20. Smith C.D., Carney J.M., Starke-Reed P.E., Oliver C.N., Stadtman E.R., Floyd R.A., Markesbery W.R. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:10540-10543.
21. Montine T.J., Neely M.D., Quinn J.F., Beal M.F., Markesbery W.R., Roberts L.J., Morrow J.D. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic. Biol. Med. 2002, 33:620-626.
22. Stadtman E.R. Protein oxidation and aging. Science 1992, 257:1220-1224.
23. Stadtman E.R., Berlett B.S. Reactive oxygen-mediated protein oxidation in aging and disease. Chem. Res. Toxicol. 1997, 10:485-494.
24. Berlett B.S., Stadtman E.R. Protein oxidation in aging, disease, and oxidative stress. JBC 1997, 272:20313-20316.
25. Cini M., Moretti A. Studies on lipid peroxidation and protein oxidation in the aging brain. Neurobiol. Aging 1995, 16:53-57.
26. Markesbery W.R., Lovell M.A. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging 1998, 19:33-36.
27. Cassarino D.S., Bennett J.P. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res. Brain Res. Rev. 1999, 29:1-25.
28. Ojaimi J., Masters C.L., Opeskin K., McKelvie P., Byrne E. Mitochondrial respiratory chain activity in the human brain as a function of age. Mech. Ageing Dev. 1999, 111:39-47.
29. Yan L.-J., Levine R.L., Sohal R.S. Oxidative damage during aging targets mitochondrial aconitase. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:11168-11172.
30. Michikawa Y., Mazzucchelli F., Bresolin N., Scarlato G., Attardi G. Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. Science 1999, 286:774-779.
31. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 1997, 23:134-147.
32. Pratico D., Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am. J. Med. 2000, 109:577-585.
33. Behl C. Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog. Neurobiol. 1999, 57:301-323.
34. Mirra S.S. The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. Neurobiol. Aging 1997, 18:S91-S94.
35. Butterfield D.A., Kanski J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech. Ageing Dev. 2001, 122:945-962.
36. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 1997, 17:2653-2657.
37. Su J.H., Deng G., Cotman C.W. Neuronal DNA damage precedes tangle formation and is associated with up-regulation of nitrotyrosine in Alzheimer's Disease brain. Brain Res. 1997, 774:193-199.
38. Hensley K., Hall N., Subramaniam R., Cole P., Harris M., Aksenov M., Aksenova M., Gabbita S.P., Wu J.F., Carney J.M., Lovell M., Markesbery W.R., Butterfield D.A. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 1995, 65:2146-2156.
39. Lyras L., Cairns N.J., Jenner A., Jenner P., Halliwell B. An assessment of oxidative damage to proteins, lipids and DNA in brain from patients with Alzheimer's disease. J. Neurochem. 1997, 68:2061-2069.
40. Aksenov M.Y., Aksenova M.V., Butterfield D.A., Geddes J.W., Markesbery W.R. Protein oxidation in the brain in Alzheimer's disease. Neuroscience 2001, 103:373-383.
41. Castegna A., Aksenov M., Aksenova M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., Markesbery W.R., Butterfield D.A. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med. 2002, 33:562-571.
42. Castegna A., Aksenov M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., Markesbery W.R., Butterfield D.A. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J. Neurochem. 2002, 82:1524-1532.
43. Palmer A.M., Burns M.A. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res. 1994, 645:338-342.
44. Sayre L.M., Zelasko D.A., Harris P.L.R., Perry G., Salomon R.G., Smith M.A. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 1997, 68:2092-2097.
45. Pratico D., Lee M.Y., Trojanowski J.Q., Rokach J., Fitzgerald G.A. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 1998, 12:1777-1783.
46. Pratico D., Clark C.M., Lee V.M., Trojanowski J.Q., Rokach J., FitzGerald G.A. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 2000, 48:809-812.
47. Lovell M.A., Markesbery W.R. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res. 2007, 35:7497-7504.
48. Lovell M.A., Gabbita S.P., Markesbery W.R. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J. Neurochem. 1999, 72:771-776.
49. Gabbita S.P., Lovell M.A., Markesbery W.R. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J. Neurochem. 1998, 71:2034-2040.
50. Lovell M.A., Markesbery W.R. Oxidatively modified RNA in mild cognitive impairment. Neurobiol. Dis. 2008, 29:169-175.
51. Nunomura A., Perry G., Pappolla M.A., Wade R., Hirai K., Chiba S., Smith M.A. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 1999, 19:1959-1964.
52. Pappolla M.A., Omar R.A., Kim K.S., Robakis N.K. Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am. J. Pathol. 1992, 140:621-628.
53. Butterfield D.A. Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Res. 2004, 1000:1-7.
54. Gibson G.E., Sheu K.F., Blass J.P. Abnormalities of mitochondrial enzymes in Alzheimer disease. J. Neural Transm. 1998, 105:855-870.
55. Bosetti F., Brizzi F., Barogi S., Mancuso M., Siciliano G., Tendi E.A., Murri L., Rapoport S.I., Solaini G. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol. Aging 2002, 23:371-376.
56. Coskun P.E., Beal M.F., Wallace D.C. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10726-10731.
57. Valla J., Berndt J.D., Gonzalez-Lima F. Energy hypometabolism in posterior cingulate cortex of Alzheimer's patients: superficial laminar cytochrome oxidase associated with disease duration. J. Neurosci. 2001, 21:4923-4930.
58. Liang W.S., Reiman E.M., Valla J., Dunckley T., Beach T.G., Grover A., Niedzielko T.L., Schneider L.E., Mastroeni D., Caselli R., Kukull W., Morris J.C., Hulette C.M., Schmechel D., Rogers J., Stephan D.A. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:4441-4446.
59. Engelhart M.J., Geerlings M.I., Ruitenberg A., van Swieten J.C., Hofman A., Witteman J.C., Breteler M.M. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002, 287:3223-3229.
60. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Wilson R.S. Vitamin E and cognitive decline in older persons. Arch. Neurol. 2002, 59:1125-1132.
61. Maxwell C.J., Hicks M.S., Hogan D.B., Basran J., Ebly E.M. Supplemental use of antioxidant vitamins and subsequent risk of cognitive decline and dementia. Dement. Geriatr. Cogn. Disord. 2005, 20:45-51.
62. Luchsinger J.A., Tang M.X., Shea S., Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch. Neurol. 2003, 60:203-208.
63. Masaki K.H., Losonczy K.G., Izmirlian G., Foley D.J., Ross G.W., Petrovitch H., Havlik R., White L.R. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000, 54:1265-1272.
64. Kang J.H., Cook N., Manson J., Buring J.E., Grodstein F. A randomized trial of vitamin E supplementation and cognitive function in women. Arch. Intern. Med. 2006, 166:2462-2468.
65. Fillenbaum G.G., Kuchibhatla M.N., Hanlon J.T., Artz M.B., Pieper C.F., Schmader K.E., Dysken M.W., Gray S.L. Dementia and Alzheimer's disease in community-dwelling elders taking vitamin C and/or vitamin E. Ann. Pharmacother. 2005, 39:2009-2014.
66. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C.W., Pfeiffer E., Schneider L.S., Thal L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N. Engl. J. Med. 1997, 336:1216-1222.
67. Petersen R.C., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., Galasko D., Jin S., Kaye J., Levey A., Pfeiffer E., Sano M., van Dyck C.H., Thal L.J. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 2005, 352:2379-2388.
68. Liu J., Killilea D.W., Ames B.N. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1876-1881.
69. Rai G., Wright G., Scott L., Beston B., Rest J., Exton-Smith A.N. Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia. Curr. Med. Res. Opin. 1990, 11:638-647.
70. Pettegrew J.W., Klunk W.E., Panchalingam K., Kanfer J.N., McClure R.J. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol. Aging 1995, 16:1-4.
71. Spagnoli A., Lucca U., Menasce G., Bandera L., Cizza G., Forloni G., Tettamanti M., Frattura L., Tiraboschi P., Comelli M., Senin U., Longo A., Petrini A., Brambilla G., Belloni A., Negri C., Cavazzuti F., Salsi A., Calogero P., Parma E., Stramba-Badiale M., Vitali S., Andreoni G., Inzoli M.R., Santus G., Caregnato R., Peruzza M., Favaretto M., Bozeglav C., Alberoni M., De Leo D., Serraiotto L., Baiocchi A., Scoccia S., Culotta P., Ieracitano D. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology 1991, 41:1726-1732.
72. Bonavita E. Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain. Int. J. Clin. Pharmacol. Ther. Toxicol. 1986, 24:511-516.
73. Thal L.J., Calvani M., Amato A., Carta A. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology 2000, 55:805-810.
74. Brooks J.O., Yesavage J.A., Carta A., Bravi D. Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. Int. Psychogeriatr. 1998, 10:193-203.
75. Thal L.J., Carta A., Clarke W.R., Ferris S.H., Friedland R.P., Petersen R.C., Pettegrew J.W., Pfeiffer E., Raskind M.A., Sano M., Tuszynski M.H., Woolson R.F. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 1996, 47:705-711.
76. Montgomery S.A., Thal L.J., Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int. Clin. Psychopharmacol. 2003, 18:61-71.
77. Bianchetti A., Rozzini R., Trabucchi M. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. Curr. Med. Res. Opin. 2003, 19:350-353.
78. Hager K., Marahrens A., Kenklies M., Riederer P., Munch G. Alpha-lipoic acid as a new treatment option for Alzheimer type dementia. Arch. Gerontol. Geriatr. 2001, 32:275-282.
79. Hager K., Kenklies M., McAfoose J., Engel J., Munch G. Alpha-lipoic acid as a new treatment option for Alzheimer's disease-a 48 months follow-up analysis. J. Neural Transm. Suppl. 2007, 189-193.
80. Kamat C.D., Gadal S., Mhatre M., Williamson K.S., Pye Q.N., Hensley K. Antioxidants in central nervous system diseases: preclinical promise and translational challenges. J. Alzheimers Dis. 2008, 15:473-493.
81. Pratico D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann. N. Y. Acad. Sci. 2008, 1147:70-78.
82. Bickford P.C., Gould T., Briederick L., Chadman K., Pollock A., Young D., Shukitt-Hale B., Joseph J. Antioxidant-rich diets improve cerebellar physiology and motor learning in aged rats. Brain Res. 2000, 866:211-217.
83. Joseph J.A., Denisova N., Villalobos-Molina R., Erat S., Strain J. Oxidative stress and age-related neuronal deficits. Mol. Chem. Neuropathol. 1996, 28:35-40.
84. Joseph J.A., Denisova N.A., Bielinski D., Fisher D.R., Shukitt-Hale B. Oxidative stress protection and vulnerability in aging: putative nutritional implications for intervention. Mech. Ageing Dev. 2000, 116:141-153.
85. Lau F.C., Shukitt-Hale B., Joseph J.A. The beneficial effects of fruit polyphenols on brain aging. Neurobiol. Aging 2005, 26(Suppl. 1):128-132.
86. Cole G.M., Morihara T., Lim G.P., Yang F., Begum A., Frautschy S.A. NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models. Ann. N. Y. Acad. Sci. 2004, 1035:68-84.
87. Crouch P.J., Cimdins K., Duce J.A., Bush A.I., Trounce I.A. Mitochondria in aging and Alzheimer's disease. Rejuvenation Res. 2007, 10:349-357.
88. Hensley K., Barnes L.L., Christov A., Tangney C., Honer W.G., Schneider J.A., Bennett D.A., Morris M.C. Analysis of postmortem ventricular cerebrospinal fluid from patients with and without dementia indicates association of vitamin E with neuritic plaques and specific measures of cognitive performance. J. Alzheimers Dis. 2011, 24:767-774.
89. Morris M.C., Tangney C.C. A potential design flaw of randomized trials of vitamin supplements. JAMA 2011, 305:1348-1349.
90. Zandi P.P., Anthony J.C., Khachaturian A.S., Stone S.V., Gustafson D., Tschanz J.T., Norton C., Welsh-Bohmer K.A., Breitner J.C. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch. Neurol. 2004, 61:82-88. C.C.S. Group.
91. Barberger-Gateau P., Raffaitin C., Letenneur L., Berr C., Tzourio C., Dartigues J.F., Alperovitch A. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology 2007, 69:1921-1930.
92. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennett D.A., Aggarwal N., Wilson R.S., Scherr P.A. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002, 287:3230-3237.
93. Chandra R.K. Effect of vitamin and trace-element supplementation on cognitive function in elderly subjects. Nutrition 2001, 17:709-712.
94. Williams J.W., Plassman B.L., Burke J., Holsinger T., Benjamin S. Preventing Alzheimer's Disease and Cognitive Decline. Evidence Report/Technology Assessment No. 193 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I.). AHRQ Publication No. 10-E005 2010, Agency for Healthcare Research and Quality, Rockville, MD.
95. Shen L., Ji H.F. Insights into the disappointing clinical trials of antioxidants in neurodegenerative diseases. J Alzheimers Dis 2010, 19:1141-1142.
96. Cotman C.W., Head E. The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. J. Alzheimers Dis. 2008, 15:685-707.
97. Head E., Liu J., Hagen T.M., Muggenburg B.A., Milgram N.W., Ames B.N., Cotman C.W. Oxidative damage increases with age in a canine model of human brain aging. J. Neurochem. 2002, 82:375-381.
98. Skoumalova A., Rofina J., Schwippelova Z., Gruys E., Wilhelm J. The role of free radicals in canine counterpart of senile dementia of the Alzheimer type. Exp. Gerontol. 2003, 38:711-719.
99. Kiatipattanasakul W., Nakamura S., Kuroki K., Nakayama H., Doi K. Immunohistochemical detection of anti-oxidative stress enzymes in the dog brain. Neuropathology 1997, 17:307-312.
100. Opii W.O., Joshi G., Head E., Milgram N.W., Muggenburg B.A., Klein J.B., Pierce W.M., Cotman C.W., Butterfield D.A. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease. Neurobiol. Aging 2008, 29:51-70.
101. Hwang I.K., Yoon Y.S., Yoo K.Y., Li H., Choi J.H., Kim D.W., Yi S.S., Seong J.K., Lee I.S., Won M.H. Differences in lipid peroxidation and Cu, Zn-superoxide dismutase in the hippocampal CA1 region between adult and aged dogs. J. Vet. Med. Sci. 2008, 70:273-277.
102. Papaioannou N., Tooten P.C.J., van Ederen A.M., Bohl J.R.E., Rofina J., Tsangaris T., Gruys E. Immunohistochemical investigation of the brain of aged dogs. I. Detection of neurofibrillary tangles and of 4-hydroxynonenal protein, an oxidative damage product, in senile plaques. Amyloid: J Protein Folding Disord. 2001, 8:11-21.
103. Rofina J.E., Singh K., Skoumalova-Vesela A., van Ederen A.M., van Asten A.J., Wilhelm J., Gruys E. Histochemical accumulation of oxidative damage products is associated with Alzheimer-like pathology in the canine. Amyloid 2004, 11:90-100.
104. Rofina J.E., van Ederen A.M., Toussaint M.J., Secreve M., van der Spek A., van der Meer I., Van Eerdenburg F.J., Gruys E. Cognitive disturbances in old dogs suffering from the canine counterpart of Alzheimer's disease. Brain Res. 2006, 1069:216-226.
105. Cotman C.W., Head E., Muggenburg B.A., Zicker S., Milgram N.W. Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction. Neurobiol. Aging 2002, 23:809-818.
106. Milgram N.W., Zicker S.C., Head E., Muggenburg B.A., Murphey H., Ikeda-Douglas C.J., Cotman C.W. Dietary enrichment counteracts age-associated cognitive dysfunction in canines. Neurobiol. Aging 2002, 23:737-745.
107. Milgram N.W., Head E., Zicker S.C., Ikeda-Douglas C., Murphey H., Muggenberg B.A., Siwak C.T., Dwight Tapp P., Lowry S.R., Cotman C.W. Long-term treatment with antioxidants and a program of behavioral enrichment reduces age-dependent impairment in discrimination and reversal learning in beagle dogs. Exp. Gerontol. 2004, 39:753-765.
108. Milgram N.W., Head E., Zicker S.C., Ikeda-Douglas C.J., Murphey H., Muggenburg B., Siwak C., Tapp D., Cotman C.W. Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study. Neurobiol. Aging 2005, 26:77-90.
109. Nippak P.M., Mendelson J., Muggenburg B., Milgram N.W. Enhanced spatial ability in aged dogs following dietary and behavioural enrichment. Neurobiol. Learn. Mem. 2007, 87:610-623.
110. Zicker S.C. Cognitive and behavioral assessment in dogs and pet food market applications. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:455-459.
111. Milgram N.W., Head E., Muggenburg B.A., Holowachuk D., Murphey H., Estrada J., Ikeda-Douglas C.J., Zicker S.C., Cotman C.W. Landmark discrimination learning in the dog: effects of age, an antioxidant fortified diet, and cognitive strategy. Neurosci. Biobehav. Rev. 2002, 26:679-695.
112. Siwak C.T., Tapp P.D., Head E., Zicker S.C., Murphey H.L., Muggenburg B.A., Ikeda-Douglas C.J., Cotman C.W., Milgram N.W. Chronic antioxidant and mitochondrial cofactor administration improves discrimination learning in aged but not young dogs. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:461-469.
113. Calabrese V., Cornelius C., Stella A.M., Calabrese E.J. Cellular stress responses, mitostress and carnitine insufficiencies as critical determinants in aging and neurodegenerative disorders: role of hormesis and vitagenes. Neurochem. Res. 2010, 35:1880-1915.
114. Calabrese V., Cornelius C., Dinkova-Kostova A.T., Calabrese E.J., Mattson M.P. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid. Redox Signal. 2010, 13:1763-1811.
115. Head E., Nukala V.N., Fenoglio K.A., Muggenburg B.A., Cotman C.W., Sullivan P.G. Effects of age, dietary, and behavioral enrichment on brain mitochondria in a canine model of human aging. Exp. Neurol. 2009, 220:171-176.
116. Siwak-Tapp C.T., Head E., Muggenburg B.A., Milgram N.W., Cotman C.W. Region specific neuron loss in the aged canine hippocampus is reduced by enrichment. Neurobiol. Aging 2008, 29:39-50.
117. Fahnestock M., Marchese M., Head E., Pop V., Michalski B., Milgram W.N., Cotman C.W. BDNF increases with behavioral enrichment and an antioxidant diet in the aged dog. Neurobiol. Aging 2010, doi:10.1016/j.neurobiolaging.2010.03.019.
118. Le T., Keithley E.M. Effects of antioxidants on the aging inner ear. Hear. Res. 2007, 226:194-202.
119. Christie L.A., Opii W.O., Head E., Araujo J.A., de Rivera C., Milgram N.W., Cotman C.W. Short-term supplementation with acetyl-L-carnitine and lipoic acid alters plasma protein carbonyl levels but does not improve cognition in aged beagles. Exp. Gerontol. 2009, 44:752-759.
120. Araujo J.A., Landsberg G.M., Milgram N.W., Miolo A. Improvement of short-term memory performance in aged beagles by a nutraceutical supplement containing phosphatidylserine, Ginkgo biloba, vitamin E, and pyridoxine. Can. Vet. J. 2008, 49:379-385.